Biogen Licenses InnoCare’s Orelabrutinib to Strengthen Multiple Sclerosis Presence
By Debadrita Paul
Pharma Deals Review: Vol 2021 Issue 8 (Table of Contents)
Published: 10 Aug-2021
DOI: 10.3833/pdr.v2021.i8.2631 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Continuing its efforts in the multiple sclerosis (MS) treatment space, Biogen has agreed to in-license InnoCare’s orelabrutinib for multiple sclerosis (MS) and certain autoimmune diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS